Article and Video CATEGORIES
This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.
We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.
dr-horton-pt-3-transition-to-molecular-pathology-audio-podcast
dr-horton-pt-3-transition-to-molecular-pathology-transcript
dr-horton-pt-3-transition-to-molecular-pathology-figures
Next, we'll turn to coverage of imaging issues in cancer management.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.
Glad to help. FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/
Hope to see...